Compare Stocks: BYSI, KZIA, CRBP, and TLSA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$0.79 -3.2%	$0.80	$0.57 ▼ $2.44	$32.37M	-0.21	613,088 shs	68,954 shs
CRBP Corbus Pharmaceuticals	$6.13 -3.3%	$9.17	$6.06 ▼ $20.56	$114.45M	2.63	1.35 million shs	834,833 shs
KZIA Novogen	$9.27 -2.1%	$12.14	$4.86 ▼ $17.40	$120.22M	2.26	288,963 shs	128,651 shs
TLSA Tiziana Life Sciences	$1.12 -1.8%	$1.01	$0.76 ▼ $2.33	$142.53M	0.45	669,807 shs	436,812 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	+1.30%	+26.53%	-57.90%	-56.02%
CRBP Corbus Pharmaceuticals	0.00%	-14.15%	-46.51%	-33.73%	-52.99%
KZIA Novogen	0.00%	-3.13%	-23.77%	-30.04%	+35.33%
TLSA Tiziana Life Sciences	0.00%	+10.89%	+14.93%	-14.50%	-42.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$0.79 -3.2%	$0.80	$0.57 ▼ $2.44	$32.37M	-0.21	613,088 shs	68,954 shs
CRBP Corbus Pharmaceuticals	$6.13 -3.3%	$9.17	$6.06 ▼ $20.56	$114.45M	2.63	1.35 million shs	834,833 shs
KZIA Novogen	$9.27 -2.1%	$12.14	$4.86 ▼ $17.40	$120.22M	2.26	288,963 shs	128,651 shs
TLSA Tiziana Life Sciences	$1.12 -1.8%	$1.01	$0.76 ▼ $2.33	$142.53M	0.45	669,807 shs	436,812 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	+1.30%	+26.53%	-57.90%	-56.02%
CRBP Corbus Pharmaceuticals	0.00%	-14.15%	-46.51%	-33.73%	-52.99%
KZIA Novogen	0.00%	-3.13%	-23.77%	-30.04%	+35.33%
TLSA Tiziana Life Sciences	0.00%	+10.89%	+14.93%	-14.50%	-42.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	1.00	Sell	N/A	N/A
CRBP Corbus Pharmaceuticals	2.60	Moderate Buy	$41.00	568.84% Upside
KZIA Novogen	2.67	Moderate Buy	$28.80	210.68% Upside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest BYSI, KZIA, CRBP, and TLSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/14/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
9/10/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/3/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00
8/26/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/26/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
8/13/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
8/13/2026	KZIA Novogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$29.00
8/7/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$52.00 ➝ $48.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	$1.75M	18.50	$0.11 per share	6.93	($0.59) per share	-1.33
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$8.40 per share	N/A
KZIA Novogen	$1.23M	97.75	N/A	N/A	($5.34) per share	-1.74
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$1.01M	-$0.12	N/A	N/A	N/A	N/A	N/A	-28.88%	11/12/2026 (Estimated)
CRBP Corbus Pharmaceuticals	-$78.54M	-$6.19	N/A	N/A	N/A	N/A	-87.05%	-74.22%	11/11/2026 (Estimated)
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BYSI, KZIA, CRBP, and TLSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	BYSI BeyondSpring	-$0.54	-$0.02	+$0.52	-$0.02	$8.77 million	N/A
8/6/2026	Q2 2026	CRBP Corbus Pharmaceuticals	-$1.26	-$1.81	-$0.55	-$1.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	0.70	0.70
CRBP Corbus Pharmaceuticals	N/A	5.71	5.71
KZIA Novogen	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
CRBP Corbus Pharmaceuticals	64.64%
KZIA Novogen	30.89%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
CRBP Corbus Pharmaceuticals	3.50%
KZIA Novogen	1.00%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	44	41.12 million	29.07 million	Optionable
CRBP Corbus Pharmaceuticals	36	18.67 million	18.02 million	Optionable
KZIA Novogen	6	12.97 million	12.84 million	No Data
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable

BYSI, KZIA, CRBP, and TLSA Headlines

Recent News About These Companies

Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Lowered by Wall Street Zen

October 3 at 1:17 AM | marketbeat.com

Tiziana Files For Orphan Drug Designation For Foralumab In MSA

September 30, 2026 | rttnews.com

Tiziana Seeks FDA Orphan Drug Designation For Intranasal Foralumab

September 30, 2026 | rttnews.com

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

September 30, 2026 | proactiveinvestors.com

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

September 30, 2026 | finance.yahoo.com

Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial

September 30, 2026 | finance.yahoo.com

Tiziana Life Sciences, Ltd. Announces First Participants Dosed In ALS BANYAN Clinical Trial Of Intranasal Foralumab

September 29, 2026 | marketscreener.comM

Tiziana Begins Phase 2a BANYAN Trial Of Intranasal Foralumab In ALS Patients

September 28, 2026 | rttnews.com

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

September 28, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

September 28, 2026 | markets.businessinsider.com

Tiziana Life Sciences Completes Last Patient Last Visit in Phase 2A Inform-Ms Trial of Intranasal Foralumab

September 22, 2026 | marketscreener.comM

BTIG Research Reaffirms "Buy" Rating for Tiziana Life Sciences (NASDAQ:TLSA)

September 22, 2026 | marketbeat.com

Tiziana Doses Final Patient In Phase 2a INFORM-MS For Foralumab; Topline Data In Oct '26

September 21, 2026 | rttnews.com

Tiziana Life Sciences to Announce Topline Data From Phase 2a Na-SPMS Trial in October

September 21, 2026 | finance.yahoo.com

Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

September 21, 2026 | markets.businessinsider.com

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

September 21, 2026 | proactiveinvestors.com

Tiziana Life Sciences Ltd(NasdaqCM:TLSA) dropped from S&P Global BMI Index

September 21, 2026 | marketscreener.comM

Why is Tiziana Life Sciences stock gaining Thursday?

September 17, 2026 | msn.com

Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up

September 17, 2026 | rttnews.com

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

September 17, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

September 17, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, KZIA, CRBP, and TLSA Company Descriptions

BeyondSpring NASDAQ:BYSI

$0.79 -0.03 (-3.24%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.73 -0.06 (-7.41%)

As of 10/2/2026 07:58 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Corbus Pharmaceuticals NASDAQ:CRBP

$6.13 -0.21 (-3.31%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.38 +0.25 (+4.14%)

As of 10/2/2026 07:30 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Novogen NASDAQ:KZIA

$9.27 -0.20 (-2.11%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.62 +0.35 (+3.82%)

As of 10/2/2026 04:37 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Tiziana Life Sciences NASDAQ:TLSA

$1.12 -0.02 (-1.75%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.11 -0.01 (-0.89%)

As of 10/2/2026 07:30 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BYSI, KZIA, CRBP, and TLSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BYSI, KZIA, CRBP, and TLSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BYSI, KZIA, CRBP, and TLSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, KZIA, CRBP, and TLSA Company Descriptions

BeyondSpring NASDAQ:BYSI

Corbus Pharmaceuticals NASDAQ:CRBP

Novogen NASDAQ:KZIA

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BYSI, KZIA, CRBP, and TLSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BYSI, KZIA, CRBP, and TLSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BYSI, KZIA, CRBP, and TLSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, KZIA, CRBP, and TLSA Company Descriptions

BeyondSpring NASDAQ:BYSI

Corbus Pharmaceuticals NASDAQ:CRBP

Novogen NASDAQ:KZIA

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools